Vatinoxan | 114914-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: Vatinoxan
• 英文别名: N-[2-[(2R,12bS)-2'-oxospiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,5'-imidazolidine]-1'-yl]ethyl]methanesulfonamide
• CAS: 114914-42-0
• 化学式: C₂₀H₂₆N₄O₄S
• 分子量: 418.5
• InChiKey: GTBKISRCRQUFNL-OXJNMPFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Vatinoxan 、 、 、 N-(2-氨基乙基)甲烷磺酰胺 、 、 三甲基氰硅烷 、 盐酸 以 水 为溶剂， 以to obtain (2R,12bS)-[2-[(cyano-1,3,4,6,7,12b-hexahydrobenzofuro-[2,3-a]quinolizine-2-yl)-amino]ethyl]methanesulfon-amide dihydrochloride的产率得到(2R,12bS)-[2-[(cyano-1,3,4,6,7,12b-hexahydrobenzofuro-[2,3-a]quinolizine-2-yl)-amino]-ethyl]methanesulfon-amide dihydrochloride
  参考文献：
  名称：

  Process for the manufacture of spirocyclic substituted benzofuroquinolizines

  摘要：

  本发明涉及一种制备N-(2-((2R,12bS)-2′-氧代-1,3,4,6,7,12b-六氢螺[苯并呋喃[2,3-a]喹啉-2,4′-咪唑啉]-3′-基)乙基)-甲磺酰胺的方法，其中使用了三甲基硅氰化物。

  公开号：

  US09409919B2
• 作为产物：
  描述：

  (2R,12bS)-1,3,4,6,7,12b-hexahydro-2-[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]-2H-benzofuro[2,3-a]quinolizine-2-carbonitrile 、 sodium methylate 以71%的产率得到
  参考文献：
  名称：

  DECAMP, ANN E.;VOLANTE, RALPH P.;KING, ANTHONY O.;SHINKAI, ICHIRO

  摘要：

  DOI：

文献信息

• PROCESS FOR THE MANUFACTURE OF SPIROCYCLIC SUBSTITUTED BENZOFUROQUINOLIZINES
  申请人：Vetcare Oy

  公开号：US20160168163A1

  公开（公告）日：2016-06-16

  The present invention relates to a process for the manufacture of N-(2-((2R,12bS)-2′-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4′-imida-zolidine]-3′-yl)ethyl)-methanesulfonamide, where in the process trimethylsilyl cyanide is used.

  本发明涉及一种制备N-(2-((2R,12bS)-2′-氧代-1,3,4,6,7,12b-六氢螺[苯并呋喃[2,3-a]喹啉-2,4′-咪唑啉]-3′-基)乙基)-甲烷磺酰胺的方法，其中使用三甲基硅氰。
• Compositions comprising substituted benzofuroquinolizine and α2-adrenergic agonists
  申请人：VETCARE OY

  公开号：US10058538B2

  公开（公告）日：2018-08-28

  The present invention relates to compositions for facilitating absorption and distribution of α2-adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α2-adrenoceptor agonist selected from substituted imidazoles and substituted thiazines and the composition is administered using parenteral extravascular administration to a subject in need of sedation.

  本发明涉及促进α2-肾上腺素能受体激动剂吸收和分布的组合物，其中所述组合物包括取代的苯并呋喃喹嗪和选自取代的咪唑类和取代的噻嗪类的α2-肾上腺素受体激动剂，该组合物通过肠外血管外给药给需要镇静的受试者。
• COMPOSITIONS COMPRISING SUBSTITUTED BENZOFUROQUINOLIZINE AND ALPHA2-ADRENERGIC AGONISTS
  申请人：Vetcare OY

  公开号：EP3217978A1

  公开（公告）日：2017-09-20
• COMPOSITIONS COMPRISING SUBSTITUTED BENZOFUROQUINOLIZINE AND alpha2-ADRENERGIC AGONISTS
  申请人：VETCARE OY

  公开号：US20170348291A1

  公开（公告）日：2017-12-07

  The present invention relates to compositions for facilitating absorption and distribution of α 2 -adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α 2 -adrenoceptor agonist selected from substituted imidazoles and substituted thiazines and the composition is administered using parenteral extravascular administration to a subject in need of sedation.
• COMPOSITIONS COMPRISING SUBSTITUTED BENZOFUROQUINOLIZINE AND PSYCHOACTIVE DRUG
  申请人：VETCARE OY

  公开号：US20190125733A1

  公开（公告）日：2019-05-02

  The present invention relates to compositions for use in sedation and/or anesthesia, where the composition comprises MK-467 and a psychoactive drug selected from opioids, benzodiazepines, NMDA receptor antagonists and combinations thereof and the composition is administered using parenteral extravascular administration to a subject in need of sedation and/or anesthesia.